[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368226-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368226-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comprehensive-pan-cancer-analysis-of-hspg2-as-a-marker-for-prognosis","Comprehensive pan-cancer analysis of HSPG2 as a marker for prognosis","","HSPG2 has been reported to relate to cancer prognosis in specific tumor types, motivating a pan-cancer evaluation of its value and underlying biology. Expression of HSPG2 was assessed across 33 tumors and matched controls using TCGA and GTEx. Cox regression and Kaplan–Meier analyses tested links to overall survival, disease-specific survival, and PFI, with associations to clinical features, immune infiltration, DNA methylation, and single-cell function. Functional relevance was supported by GO/KEGG enrichment of HSPG2 co-expressed genes, and diagnostic performance was examined and validated by qPCR.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-pan-cancer-analysis-of-hspg2-as-a-marker-for-prognosis/368226/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-pan-cancer-analysis-of-hspg2-as-a-marker-for-prognosis/368226.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of the study on HSPG2?","Question",{"text":63,"@type":64},"To evaluate the prognostic value of HSPG2 in pan-cancer and investigate potential mechanisms behind its associations with clinical outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and statistical analyses were used to assess HSPG2?",{"text":68,"@type":64},"TCGA and GTEx were used to examine HSPG2 expression across 33 tumors. Univariate Cox regression and Kaplan–Meier survival analysis were applied to study overall survival, disease-specific survival, and progression-free interval.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about HSPG2’s prognostic and diagnostic relevance?",{"text":72,"@type":64},"Multivariate regression identified HSPG2 as an independent prognostic factor for DSS, OS, and PFI in BLCA and MESO. HSPG2 also showed diagnostic efficacy for BLCA and MESO, with qPCR and western blot indicating higher expression in mesothelioma versus normal controls.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368226,1790387718,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Chen et al. BMC Medical Genomics (2025) 18:33 [https://doi.org/10.1186/s12920-025-02103-w](https://doi.org/10.1186/s12920-025-02103-w)  \nBMC Medical Genomics  \n RESEARCH Open Access  \nComprehensive pan-cancer analysis of HSPG2 as a marker for prognosis  \nFangjun Chen1†, Xing Gu2† and Guangliang Qiang3*  \nAbstract  \nBackground In recent years, several studies have shown that HSPG2 is associated with the prognosis of specific cancers. The aim of this study was to investigate the prognostic value of HSPG2 in pan-cancer and to analyze its possible mechanisms.  \nMethods We used The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) to explore the expression of HSPG2 in 33 tumors and corresponding controls. Univariate Cox regression and Kaplan–Meier survival analysis were applied to detect the effects of HSPG2 on overall survival (OS), disease-specific survival (DSS), and progressionfree interval (PFI) in patients with these tumors, and to analyze the relationship between HSPG2 and clinical characteristics. And we further analyzed the relationship between HSPG2 and immune infiltration, DNA methylation and single cell function. And GO and KEGG enrichment analyses were performed using HSPG2 co-expressed genes. Finally, we explored the diagnostic efficacy of HSPG2 for diseases of interest and validated it using qPCR experiment.  \nResults HSPG2 was lowly expressed in 17 cancers and highly expressed in 11 cancers, and was correlated  \nwith patient’s clinical characteristics in many cancers. Multivariate regression analysis showed that HSPG2  \nwas an independent prognostic factor for DSS, OS, and PFI in bladder urothelial carcinoma (BLCA) and Mesothelioma (MESO) . HSPG2 was correlated with DNA methylation, single-cell function, and immune infiltration in a variety of cancers. HSPG2 exhibited a good diagnostic efficacy for BLCA and MESO. qPCR and western blot results showed that HSPG2 expression was increased in mesothelioma compared to normal controls.  \nConclusion These findings suggest that HSPG2 could be considered as a potential diagnostic and prognostic marker for BLCA and MESO.  \nKeywords Pan cancer, HSPG2, Prognosis, Diagnosis, BLCA, MESO  \n†Fangjun Chen and Xing Gu contributed equally to this work.  \n*Correspondence: Guangliang Qiang [pkudd@bjmu.edu.cn](pkudd@bjmu.edu.cn)  \n1 Department of Thoracic Surgery, China-Japan Friendship Institute of Clinical Medicine, No. 2 Yinghua East Street, Chaoyang District, Beijing 100029, China  \n2 College of Foreign Languages, Chongqing Medical University, No.1 Yixueyuan Road, Yuzhong District, Chongqing 400016, China  \n3 Department of Thoracic Surgery, Peking University Third Hospital, No.49 Huayuan North Road, Haidian District, Beijing 100191, China  \nIntroduction  \nCancer is the leading cause of death and a major obstacle to increasing life expectancy worldwide [1]. And cancer incidence has increased among adolescents and young adults (AYAs), but mortality has decreased significantly between 1990 and 2019 [2]. The resulting healthcare burden looms large. It is estimated that in 2024, 611,720 people will die of cancer in the United States, equating to about 1,680 deaths per day, and cancer patients are increasingly shifting from the elderly to the middle-aged [3]. This is also similar in China, where cancer incidence has increased for all cancers among young people aged  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in","cbCaifBkxTK9taUH","https://ap.wps.com/l/cbCaifBkxTK9taUH","pdf",4142844,21,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"What was the main objective of the study on HSPG2?\",\"answer\":\"To evaluate the prognostic value of HSPG2 in pan-cancer and investigate potential mechanisms behind its associations with clinical outcomes.\"},{\"question\":\"Which datasets and statistical analyses were used to assess HSPG2?\",\"answer\":\"TCGA and GTEx were used to examine HSPG2 expression across 33 tumors. Univariate Cox regression and Kaplan–Meier survival analysis were applied to study overall survival, disease-specific survival, and progression-free interval.\"},{\"question\":\"What did the study find about HSPG2’s prognostic and diagnostic relevance?\",\"answer\":\"Multivariate regression identified HSPG2 as an independent prognostic factor for DSS, OS, and PFI in BLCA and MESO. HSPG2 also showed diagnostic efficacy for BLCA and MESO, with qPCR and western blot indicating higher expression in mesothelioma versus normal controls.\"}]","Comprehensive pan-cancer analysis of HSPG2 as a marker for prognosis | PDF",1790175754,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5bd238485e79c13c9a338357b9ff2be.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ae7f71367e49ba7c823bec9a6851687.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21c7885883f1f08bce35b1ad6c160aef.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a97046b6a2bb7d831b7eef4004047f9a.webp",980,1301]